As of February 16, 2026, Sanofi is actively pursuing an acquisition of Ocular Therapeutix (NASDAQ: OCUL) and is preparing a "sweetened," higher bid after a previous offer was rejected, reported by MarketMinute. The potential deal is centered on Ocular's lead drug candidate for wet AMD, Axpaxli, with pivotal Phase 3 results expected on February 17, 2026, according to FinancialContent.
Market Data 
Markets 
AI
